葡萄糖-6-磷酸脱氢酶缺乏症
溶血性贫血
氧化应激
脱氢酶
下调和上调
葡萄糖-6-磷酸脱氢酶
药物开发
基因
生物
医学
免疫学
药理学
生物信息学
生物化学
酶
药品
作者
Adriana A. Garcia,Ana Koperniku,Julio Cesar Batista Ferreira,Daria Mochly‐Rosen
标识
DOI:10.1016/j.tips.2021.07.002
摘要
Glucose-6-phosphate dehydrogenase (G6PD) maintains redox balance in a variety of cell types and is essential for erythrocyte resistance to oxidative stress. G6PD deficiency, caused by mutations in the G6PD gene, is present in ~400 million people worldwide, and can cause acute hemolytic anemia. Currently, there are no therapeutics for G6PD deficiency. We discuss the role of G6PD in hemolytic and nonhemolytic disorders, treatment strategies attempted over the years, and potential reasons for their failure. We also discuss potential pharmacological pathways, including glutathione (GSH) metabolism, compensatory NADPH production routes, transcriptional upregulation of the G6PD gene, highlighting potential drug targets. The needs and opportunities described here may motivate the development of a therapeutic for hematological and other chronic diseases associated with G6PD deficiency.
科研通智能强力驱动
Strongly Powered by AbleSci AI